|
DEA
Congressional Testimony
February 12, 2004
Statement
of
Karen
P. Tandy
Administrator
Drug
Enforcement Administration
Before
the
Committee
on International Relations
U.S. House of Representatives
February
12, 2004
"United
States Policy Towards Narco-Terrorism in Afghanistan"
Chairman Hyde, Ranking
Member Lantos and distinguished members of the Committee, thank you for
the invitation to testify today on the important issue of opium production
in Afghanistan and its potential links to terrorism.
Overview
Afghan drug production
is a priority for the DEA that guides our enforcement strategy in the
region. As you know, opium production in Afghanistan has resumed over
the last two years, although it is still lower than the highest level
reached under the Taliban. While we expect that only a small portion of
the resulting opium and heroin will ultimately reach the United States,
these drugs are of great concern because they increase worldwide supply
and have the potential to fund terrorists and other destabilizing groups.
Because the situation inside Afghanistan presents unique challenges to
law enforcement, the DEA has successfully acted with neighboring countries
to control the spread of Afghan opium and heroin through Operation Containment.
I have just returned
from Kabul where Assistant Secretary of State Robert Charles, other senior
officials representing the United States, and I participated in discussions
with Afghanistan Transitional Authority President Hamid Karzai, United
Nations Office of Drugs and Crime Director Antonio Costa and other representatives
from Afghanistan and the European Union on the challenges posed by Afghan
drug production. The international drug control community shares our view
that concerted multilateral efforts will be required to effectively address
these problems. I look forward to discussing each of these important issues
with the Committee.
Afghanistan
Poppy Production and the U.S. Response
Significant Opium
Production Resumes
Afghanistan is a
major source country for the cultivation, processing and trafficking of
opiate products. It has historically produced significant quantities of
opium, and accounted for over 70 percent of the world's supply in the
year 2000, when the United States government estimated Afghan opium production
at 3,656 metric tons. In 2001, the Taliban banned the cultivation of opium
poppy. The DEA believes that the ban was likely an attempt by the Taliban
to raise the price of opium which had fallen significantly due to the
abundant supply produced in years prior to 2001. Regardless of intent,
production plummeted to 74 metric tons in 2001.
With the fall of
the Taliban, Afghan growers resumed cultivation despite renewal of the
ban on poppy growth by the Karzai government. Opium production has returned
to its historically substantial amounts, although it is important to emphasize
that it has not yet reached the level of poppy recorded in 2000. In 2003,
the United States Government officially estimated production of 2,865
metric tons of oven-dried opium from 61,000 hectares of poppy cultivation.
Afghanistan:
Estimated Annual Potential Opium Production (Metric Tons)
| 2003 |
2002 |
2001 |
2000 |
1999 |
1998 |
1997 |
1996 |
| 2,865 |
1,278 |
74 |
3,656 |
2,861 |
2,340 |
2,184 |
2,099 |
Heroin Production
and Movement
The opium produced
in Afghanistan is readily made into narcotics to be sold on the international
market, much of which eventually reaches users in Europe. While Europe
is the primary destination for Afghan heroin, much of the opium remains
in Southwest Asia for local consumption. Laboratories convert the opium
into morphine base, white heroin, or one of several grades of brown heroin.
Large processing laboratories are located in southern Afghanistan; smaller
laboratories are located in other areas of the country, including the
Nangarhar Province. In addition, morphine base produced in Afghanistan
is shipped to traffickers based in Turkey and converted to heroin.
Transporting converted
opium from Afghanistan is no easy task. Larger than the State of Texas,
Afghanistan is landlocked, forcing traffickers to rely on challenging
overland routes to move drug shipments out of the country. In addition
to the traditional smuggling routes through Iran to Turkey, our intelligence
reports indicate continued movement of heroin shipments north from Afghanistan
through the Central Asian States, notably Tajikistan, to Russia. Some
of the heroin is consumed in Russia, while a portion moves on to other
markets. Afghan heroin also moves through India enroute to international
markets and continues to be trafficked through Pakistan, where heroin
is smuggled out through airports and vessels leaving the Pakistan coast.
DEA intelligence
suggests that relatively little Afghan heroin is ultimately destined for
the United States, although we continue to monitor carefully the market
for potential new trends. Through the Heroin Signature Program (HSP),
the DEA Special Testing and Research Laboratory analyzes samples from
seizures at ports of entry and other randomly selected sources to determine
their purity and geographic origin. In 2002, Southwest Asian heroin (which
includes Afghan heroin) accounted for ten percent of the weight of all
samples analyzed. Preliminary data for 2003 indicate that Southwest Asian
heroin was eight percent by weight of the sample, although the 2003 survey
is not yet complete. Similarly, the Domestic Monitor Program (DMP), which
examines samples bought undercover on American streets to monitor their
characteristics, showed that Southwest Asian heroin represented four percent
of samples in 2002 and five percent in 2003. Neither HSP nor DMP results
should be equated with market share, but rather suggest availability over
time.
The DEA's Response
Inside Afghanistan
Opium production
in Afghanistan nonetheless is a significant concern and a priority for
the DEA because of its impact on worldwide drug supply and its potential,
as I will discuss later, to provide financial support to terrorists and
other destabilizing groups. In assessing strategies to control and respond
to this production, it is important to understand the significant operational
obstacles we face in Afghanistan. Three decades of civil war and unrest
have left the criminal justice system in disarray. Outside of Kabul, the
country is not uniformly controlled by the central government. DEA has
no national or local drug enforcement counterparts and Afghanistan lacks
many of the most basic elements of its criminal justice institutions.
Due to security constraints, DEA's presence in Afghanistan is limited
to two agents, whose movement and ability to conduct traditional drug
enforcement operations are severely restricted.
The DEA's Kabul Country
Office, reopened in February 2003, nonetheless is making superb contributions
under these difficult circumstances. DEA agents continue to gather and
disseminate intelligence to U.S. and British law enforcement and intelligence
agencies. We have made the collection and analysis of drug intelligence
a priority within Afghanistan and Central Asia and are supporting a Department
of Defense initiative to open an intelligence "fusion center"
for multinational information sharing. Our country office also continues
to debrief confidential sources in Kabul and supports domestic and foreign
drug enforcement operations.
The DEA also works
with other federal agencies on law enforcement matters in Afghanistan.
Three months ago, DEA's Kabul Country Office personnel assisted the State
Department's Bureau of International Narcotics and Law Enforcement Affairs
and the U.S. Army, traveling by convoy from Kabul to Kunduz to recruit
police officers and soldiers for the Afghanistan Police Force and to conduct
a site survey for a new Regional Law Enforcement Training Center to be
funded by the United States. The mission was successful: for example,
the Konduz RTC will be operational in March.
Operation Containment
The challenges to
law enforcement within Afghanistan strongly suggested the need for a simultaneous,
concerted effort to control Afghan drugs in neighboring countries before
they can spread to broader markets. Operation Containment is a large-scale,
multinational law enforcement initiative begun in early 2002 under the
leadership of the DEA and with special support from Congress. Emphasizing
coordination and information sharing among nineteen countries from Central
Asia, the Caucuses, Europe and Russia, the program aims to implement a
joint strategy to deprive drug trafficking organizations of their market
access and international terrorist groups of financial support from drugs,
precursor chemicals, weapons, ammunition and currency. It has been enormously
successful, and I would like to thank the Committee for its strong support
for this initiative.
The DEA supports
Operation Containment worldwide, particularly in Pakistan, Turkey, Russia,
and Central Asia. We have expanded existing offices in Europe and Southwest
Asia and opened a new office in Uzbekistan. The DEA has assigned Special
Agents to its Kabul, Ankara, Istanbul, Tashkent, Moscow and London Offices
to support Operation Containment. In addition, one Intelligence Specialist
and one support position are assigned in Ankara and one support position
is assigned in Tashkent to support Operation Containment. DEA is also
seeking approval to assign two Special Agents to Kyrgyzstan and additional
agent and intelligence personnel to Uzbekistan and Brussels for Operation
Containment.
Another key element
is the Sensitive Investigative Unit (SIU), a program that has been highly
successful in other regions of the world. An SIU is made up of host nation
law enforcement personnel, who are individually screened to protect against
corruption and then specially trained and equipped to DEA standards. We
have established a new DEA SIU in Uzbekistan, and the DEA SIU in Pakistan
has made several significant seizures. These DEA-lead units provide critical
and valuable assistance to anti-drug efforts in their countries.
Intelligence sharing
is also a priority, with the initiative supporting regional intelligence
sharing centers in Bucharest, Romania and Bishkek, Kyrgyzstan and a short-term
Fusion Center program in Tashkent, Uzbekistan. DEA has temporarily assigned
an Intelligence Analyst to the Bucharest intelligence center.
Operation Containment
has been a great success. Since March 2002, it has resulted in 23 significant
seizures of narcotics and precursor chemicals and led to the dismantlement
and disruption of several major distribution/transportation organizations
involved in the Southwest Asian drug trade. These include the disruption
three months ago in Istanbul of the Galip Kuyucu transportation group,
which was one of the most significant heroin traffickers in Turkey and
a Justice Department international priority target. The Turkish National
Police, working with the DEA and Her Majesty's Customs and Excise, seized
495 kilograms of heroin, and disrupted this organization, which was regularly
transporting similarly sized amounts of drugs throughout Western Europe.
This investigation also led to the arrest of Urfi Cetinkaya, a major source
of heroin supply with direct ties to Afghan drug traffickers.
Another significant
success for Operation Containment was the arrest of 15 members of the
Attila Ozyildirim heroin trafficking organization and the seizure of 7.4
tons of morphine base in Turkey during March 2002. This is the largest
seizure of morphine base ever made. To put the magnitude of this seizure
in perspective - the amount seized was more than four times greater than
the total worldwide morphine base seizures made in 2000. Morphine base
can be converted to heroin at a ratio of 1:1.
Drug Enforcement
Training
The DEA is also working
to build law enforcement capability and cooperation in Afghanistan and
throughout the region. During October 2002, we participated along with
officials from Afghanistan's Interior Ministry in a United Nations International
Narcotics Control Board conference in Tashkent, Uzbekistan regarding Operation
Topaz. Operation Topaz is intended to bring together law enforcement in
several nations to detect and seize suspicious and unauthorized shipments
of acetic anhydride, the primary precursor chemical used in the production
of heroin.
We have particularly
emphasized training for foreign law enforcement agencies, including a
three week seminar conducted last September in the United States for high-level
police managers. General Hilaluddin Hilal, Afghanistan's Deputy Interior
Minister of Security Affairs, attended the course, which took place at
both DEA Headquarters and the DEA Academy in Quantico, Virginia. I participated
in this seminar personally as did members of the DEA's senior management,
and we believe that it helped to begin and improve important partnerships
with and among DEA and the international agencies involved.
During 2004, the
DEA plans to conduct Drug Unit Commander training courses in Turkey and
Uzbekistan. These one-week courses are funded through Operation Containment
and are geared for supervisors of operational drug units. We anticipate
that five to ten participants from throughout Afghanistan will attend
each school. In addition, DEA is expanding its training efforts throughout
the region during 2004, with training courses scheduled in Turkmenistan,
Uzbekistan, Tajikistan, Thailand and India.
Links
between Terrorism and the Afghan Drug Trade
DEA's Role in
Fighting Terrorism
Mr. Chairman, the
Committee has also asked me to address the potential links between terrorism
and trafficking of Afghan opium and heroin. Last September, President
Bush thanked DEA agents in a speech at Quantico, Virginia. He said "By
keeping drug money from financing terror, you're playing an important
part of this war." And we will continue doing so.
A narco-terrorist
organization is an organized group that is complicit in the activities
of drug trafficking to further or fund premeditated, politically motivated
violence to influence a government or group of people. Although the DEA
does not specifically target terrorists, some of the powerful international
drug trafficking organizations we have targeted have never hesitated to
use violence and terror to advance their interests. As of October 2003,
the DEA has identified seventeen Foreign Terrorist Organizations, as designated
by the Department of State, with potential ties to the drug trade. More
generally, we know that drugs and terror frequently share a common ground
of geography, money, and violence.
Our headquarters
is only about 700 yards from the Pentagon, and DEA shook, literally and
figuratively, when the terrorists attacked on September 11, 2001. DEA
mobilized resources immediately, lending more than one hundred Special
Agents to the Sky Marshal program, supporting the FBI investigation through
the El Paso Intelligence Center (EPIC) and fifty loaned Intelligence Analysts,
and debriefing all of its Confidential Sources in an attempt to gain any
available information on the attacks. Since the attack, EPIC has processed
well over 200,000 terrorism inquiries.
During December 2001,
the DEA formed a Special Coordination Unit at its Special Operations Division.
This multi-agency unit coordinates all DEA intelligence and investigations
having a possible nexus to terrorism and shares information with agencies
responsible for coordinating terrorist intelligence and investigations.
DEA drug investigations have generated such narco-terrorist related intelligence
and investigations both domestically and internationally. DEA also has
assigned personnel to various FBI Joint Terrorism Task Forces across the
country and maintains liaison with the Department of Homeland Security.
Evaluating Links
between Drugs and Terrorism
Past domestic investigations
have shown the clear potential for drug money to fund terrorist groups.
In October 2001, a joint DEA/FBI investigation targeting two heroin traffickers
in Peshawar, Pakistan led to the seizure of 1.4 kilograms of heroin in
Maryland and identification of two suspected money launderers, one with
suspected ties to al Qaida. Similarly, Operation Marble Palace in 2001
determined that several members of a targeted heroin trafficking organization
had possible ties to the Taliban and that a connected bank account had
been used to launder proceeds to alleged Taliban supporters in Pakistan.
Based on that demonstrated
potential, many have suggested that there must be financial ties between
drugs and terrorism in Afghanistan. At this time, we do not have evidence
capable of sustaining an indictment of direct links between terrorism
and narcotics trafficking groups within Afghanistan. To the extent that
allegations have been raised based on more than speculation, they generally
come from single sources. Clear corroborating evidence of such sources
has been difficult to obtain, in part because many traditional investigative
techniques cannot be used within the country for reasons I have previously
explained.
Raw intelligence
and uncorroborated confidential sources continue to indicate possible
relationships between drug traffic and terrorist groups within Afghanistan.
The DEA will continue to assign the highest priority to investigating
any information linking drugs to terrorism. We will do so in cooperation
with our law enforcement and intelligence partners, and we will aggressively
work to gather and document intelligence relating to drug activity that
may finance terrorism.
The Drug/Financial
Fusion Center recently created by Congress will use the Foreign Terrorist
Tracking Task Force's architecture to enhance capabilities to uncover
links between drug trafficking and terrorism. Investigative links between
drug trafficking and money laundering organizations and known terrorist
organizations will be shared with the FBI, the Department of Homeland
Security, the Treasury Department and the intelligence community. Additionally,
our intelligence programs continue to work closely with law enforcement
and the intelligence community to identify and anticipate emerging threats
posed by the links between drug trafficking and terrorism.
Conclusion
Mr. Chairman, control
of drug production in Afghanistan and its potential ties to terrorism
is an agencywide priority for the DEA. I very much appreciate the opportunity
to testify before the Committee today. I will be happy to answer any questions
you may have.
|